-20℃ 3 years powder
-80℃ 2 years in solvent
Centrinone-B (LCR-323) is a potent and highly selective inhibitor of PLK4 (Ki: 0.59 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | inquiry | 98.00 | |
5 mg | inquiry | 146.00 | |
10 mg | inquiry | 239.00 | |
50 mg | inquiry | 971.00 | |
100 mg | inquiry | inquiry | |
200 mg | inquiry | inquiry | |
1 mL * 10 mM (in DMSO) | inquiry | 201.00 |
Description | Centrinone-B (LCR-323) is a potent and highly selective inhibitor of PLK4 (Ki: 0.59 nM). |
Targets&IC50 | PLK4 :ic50 0.59 nM (ki), PLK4 G95L :ic50 497.53 nM (ki), Aurora A :ic50 1239 nM (ki), Aurora B :ic50 5597.14 nM (ki), |
In vitro | Centrinone-B (0-200 nM) significantly decreases cell viability of PLK4-centriole conjunction melanoma cell lines except for p53 mutant SK-MEL-28, and this effect is via inhibition of PLK4. Centrinone-B slightly binds to Aurora A and Aurora B (Kis: 1239 nM and 5597.14 nM). Centrinone-B exhibits >1000-fold selectivity for Plk4 over Aurora A/B in vitro and does not affect cellular Aurora A or B substrate phosphorylation at concentrations that deplete centrosomes [1]. Inhibition of PLK4 by Centrinone-B also induces apoptosis in human melanoma cell lines [2]. |
Synonyms | LCR-323 |
Purity | 98.00% |
Molecular Weight | 631.67 |
Formula | C27H27F2N7O5S2 |
CAS No. | 1798871-31-4 |
-20℃ 3 years powder
-80℃ 2 years in solvent
DMSO: 25 mg/mL (39.58 mM), Need ultrasonic
H2O: < 0.1 mg/mL (insoluble)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
Safe and effective drug dosing is necessary, regardless of its purpose of administration. Learn More
bottom
Answers to questions you may have can be found in the Inhibitor Handling Instructions. Topics include how to prepare stock solutions, how to store Products, and issues that need special attention for cell-based assays and animal experiments.